ORIC Pharmaceuticals, Inc. ORIC announced that it has collaborated with pharma giants Bayer BAYRY and Janssen Research & Development, LLC, a Johnson & Johnson JNJ company, to support its ongoing study ...
ORIC Pharmaceuticals, Inc. ORIC announced that it has entered into a clinical development collaboration with pharma giant Pfizer PFE for a potential phase II study evaluating ORIC-533 for multiple ...
Oric Pharmaceuticals’ previously announced plan to focus resources on its two most advanced oncology drugs comes with a sting in its tail—the therapeutic-resistance-focused biotech is laying off 20% ...
ORIC Pharmaceuticals (NASDAQ: ORIC) is a small-cap pharma stock. It aims to make a difference with its potentially “best-in-class” treatments. The company’s shares have not had a great year, returning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback